On September 24, the "Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs", co-sponsored by a number of industry leading institutions and enterprises such as Hotgen, was officially launched at the 5th China Healthcare Decision Makers Conference. The alliance aims to integrate upstream and downstream resources of the industrial chain, promote the development and internationalization of innovative drugs with global First-in-Class (FIC) potential, and help the Chinese biopharmaceutical industry to leap from "running" to "leading".
As a founding member enterprise of the Alliance, Sungen has always adhered to the mission of "innovation leading the future and benefiting human health", focusing on the development of original drugs with clinical value and global competitiveness. Sungen joins the Zhongguancun FIC Global Strategic Development Alliance for Innovative Drugs, which is a key step in deepening the strategy of innovative drugs, strengthening industry coordination, and pushing Chinese original new drugs into the world.
Since 2024, with the number of domestic clinical pipelines of innovative drugs occupying the first place in the world, the Chinese pharmaceutical industry has successfully transformed into an important force in global innovative drug research and development. Correspondingly, as an inevitable stage of pharmaceutical industry upgrading, China's original innovative FIC pipeline is also rising rapidly, accounting for 24% of the world. Chinese pharmaceutical companies focusing on FIC drug development have become a pivotal link in the global pharmaceutical industry chain.
In order to accelerate the chain development of Chinese FIC drugs from R & D to landing, from local to global, Sungen has actively engaged in the alliance construction. At present, there are more than 40 alliance member enterprises, and more than 600 innovative drug pipelines are under development, including 172 FIC pipelines, with a total transaction volume of about 16.88 billion US dollars, showing strong resource aggregation and innovation vitality.
In the future, Sungen will build a global FIC new drug empowerment platform with alliance partners based on its core advantages in innovative drug research and development, clinical transformation and industrialization, break through resource and market bottlenecks, help China's original new drugs to set a benchmark on the international stage and create a shining "global business card for innovative Chinese innovative drugs".
Updated: Nov 26, 2025
